IL-31 Antikörper (N-Term)
Kurzübersicht für IL-31 Antikörper (N-Term) (ABIN500004)
Target
Alle IL-31 (IL31) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- IL-31 antibody was raised against a 16 amino acid peptide from near the amino terminus of mouse IL-31.
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- Murine IL-31 (N-Terminus) Peptide
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
ELISA. Western Blot: 2.5 - 5 μg/mL. Immunohistochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- PBS containing 0.02 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
-
- IL-31 (IL31) (Interleukin 31 (IL31))
-
Andere Bezeichnung
- Interleukin-31 / IL31
-
Hintergrund
- Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells (1,2). IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor (2). In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways (3). RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells . IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development (1,4).Synonyms: IL-31
-
Gen-ID
- 76399
-
UniProt
- Q6EAL8
Target
-